mrna 1273 spikevax (Moderna)

About

News

Press Release

Team

Advisors

Partners

Contact

Bioz Stars

Bioz vStars

Buy from Supplier

Structured Review

Moderna mrna 1273 spikevax
Mrna 1273 Spikevax, supplied by Moderna, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/mrna+1273+spikevax/1273+mrna+%D0%B8%D0%BB%D0%B8/pmc13010108-17-66-65
Average 86 stars, based on 1 article reviews

mrna 1273 spikevax - by Bioz Stars, 2026-09

86/100 stars

Images

other:

Article Title: The PHH-1V HIPRA vaccine: a new tool in the vaccination strategy against COVID-19
Article Snippet: In the preliminary results of that Phase 3 study, PHH-1V induced a strong humoral response at Day 14 after immunization independently of the previous vaccination (BNT162b2, ChAdOx1-S [Vaxzevria®, AstraZeneca, UK], mRNA 1273 [SPIKEVAX®, Moderna Biotech, Spain], Ad26.COV2-S [Jcovden®, Jannsen-Cilag International NV]), with no differences in safety profile [ , ].

Article Title: The PHH-1V HIPRA vaccine: a new tool in the vaccination strategy against COVID-19.
Article Snippet: In the preliminary results of that Phase 3 study, PHH-1V induced a strong humoral response at Day 14 after immunization independently of the previous vaccination (BNT162b2, ChAdOx1-S [Vaxzevria®, AstraZeneca, UK], mRNA 1273 [SPIKEVAX®, Moderna Biotech, Spain], Ad26.COV2-S [Jcovden®, Jannsen-Cilag International NV]), with no differences in safety profile [15,21].

Article Title: Research progress of mRNA vaccines for infectious diseases
Article Snippet: mRNA-1273 (Spikevax) , mRNA , 2 doses; Day 0 + 28; IM , Moderna + National Institute of Allergy and Infectious Diseases (NIAID) , Phase 4 , NCT04760132.

Vaccines:

Article Title: Low risk of severe COVID-19 in vaccinated people with multiple sclerosis: a nationwide Norwegian study
Article Snippet: .. Participants received one or more of the following SARS-CoV-2 vaccines: BNT162b2 Comirnaty (Pfizer–BioNTech), mRNA-1273 Spikevax (Moderna), ChAdOx1 (AstraZeneca/Oxford) or the bivalent boosters Comirnaty BA.4–5 and Spikevax BA.4–5. ..

Article Title: Immunogenicity, effectiveness, safety and psychological impact of COVID-19 mRNA vaccines
Article Snippet: .. Of all vaccines studied, 11 % are mRNA vaccines, of which two, mRNA 1273 Spikevax (developed by Moderna) and BNT162b Comirnaty (developed by Pfizer-BioNTech ltd), were the first to be approved for emergency use in several countries. .. Of the viral vector vaccines, which accounted for the remaining percentage of vaccines tested, were approved AstraZeneca (ChAdOx1, developed by Jenner Institute of Oxford University), Johnson & Johnson (JNJ-78436734, developed by Janssen Pharmaceutical companies), and Sputnik-V (Gam-COVID-vac, developed by N. F. Gamaleya Federal Research Center for Epidemiology & Microbiology).

Article Title: Advances in mRNA-LNP lung-targeted delivery strategies
Article Snippet: In 2018, the U.S. FDA approved Patisiran (brand name Onpattro), the first LNP-formulated siRNA therapeutic developed by Alnylam Pharmaceuticals[52]. .. In 2020, two mRNA-based COVID-19 vaccines utilizing LNP technology were authorized: BNT162b2 (Comirnaty) by Pfizer/BioNTech and mRNA-1273 (Spikevax) by Moderna[53]. .. In 2024, Moderna’s mRNA-1345 (mRESVIA), a vaccine targeting respiratory syncytial virus (RSV), was also approved[54].

Article Title: A transferable SARS-CoV-2 IRES module enables dual translation initiation for enhanced antigen expression in COVID-19 mRNA vaccines
Article Snippet: .. In contrast, in uncapped RNAs, translation may also proceed through internal ribosome entry site (IRES), which recruits ribosomes independent of the 5′ cap., Such IRES-mediated initiation is widely exploited by RNA viruses to ensure protein synthesis under conditions that suppress host cap-dependent translation., Approved COVID-19 mRNA vaccines rely exclusively on cap-dependent translation and employ optimized 5′UTRs to maximize cap-dependent translation and antigen yields., For example, Moderna’s mRNA-1273 (Spikevax) uses a synthetic 57-nt 5′UTR, while the Pfizer-BioNTech BNT162b2 vaccine employs a sequence derived from the 5′UTR of human α-globin ( HBA1 ) mRNA. .. In contrast, CureVac’s first-generation vaccine CVnCoV used a very short artificial 5′UTR sequence.

Article Title: A transferable SARS-CoV-2 IRES module enables dual translation initiation for enhanced antigen expression in COVID-19 mRNA vaccines
Article Snippet: .. In contrast, 38 in uncapped RNAs, translation may also proceed through internal ribosome entry site (IRES), 39 which recruits ribosomes independent of the 5′ cap.4,5 Such IRES-mediated initiation is 40 widely exploited by RNA viruses to ensure protein synthesis under conditions that suppress 41 host cap-dependent translation.4,5 42 Approved COVID-19 mRNA vaccines rely exclusively on cap-dependent translation and 43 employ optimized 5′UTRs to maximize cap-dependent translation and antigen yields.1,6 For 44 example, Moderna’s mRNA-1273 (Spikevax) uses a synthetic 57-nt 5′UTR, while the Pfizer–45 BioNTech BNT162b2 vaccine employs a sequence derived from the 5′UTR of human α-46 globin (HBA1) mRNA.6 In contrast, CureVac’s first-generation vaccine CVnCoV used a very 47 short artificial 5′UTR sequence.7 Its second-generation vaccine, CV2CoV, incorporated a 48 longer, optimized 5′UTR derived from human hydroxysteroid 17β-dehydrogenase 4 49 (HSD17B4), resulting in improved antigen expression and enhanced immunogenicity.7 These 50 Jo urn al Pr e-p roo f 3 examples highlight the 5′UTR as a key determinant of mRNA translational potency and 51 overall vaccine performance. ..

Sequencing:

Article Title: A transferable SARS-CoV-2 IRES module enables dual translation initiation for enhanced antigen expression in COVID-19 mRNA vaccines
Article Snippet: .. In contrast, 38 in uncapped RNAs, translation may also proceed through internal ribosome entry site (IRES), 39 which recruits ribosomes independent of the 5′ cap.4,5 Such IRES-mediated initiation is 40 widely exploited by RNA viruses to ensure protein synthesis under conditions that suppress 41 host cap-dependent translation.4,5 42 Approved COVID-19 mRNA vaccines rely exclusively on cap-dependent translation and 43 employ optimized 5′UTRs to maximize cap-dependent translation and antigen yields.1,6 For 44 example, Moderna’s mRNA-1273 (Spikevax) uses a synthetic 57-nt 5′UTR, while the Pfizer–45 BioNTech BNT162b2 vaccine employs a sequence derived from the 5′UTR of human α-46 globin (HBA1) mRNA.6 In contrast, CureVac’s first-generation vaccine CVnCoV used a very 47 short artificial 5′UTR sequence.7 Its second-generation vaccine, CV2CoV, incorporated a 48 longer, optimized 5′UTR derived from human hydroxysteroid 17β-dehydrogenase 4 49 (HSD17B4), resulting in improved antigen expression and enhanced immunogenicity.7 These 50 Jo urn al Pr e-p roo f 3 examples highlight the 5′UTR as a key determinant of mRNA translational potency and 51 overall vaccine performance. ..

Derivative Assay:

Article Title: A transferable SARS-CoV-2 IRES module enables dual translation initiation for enhanced antigen expression in COVID-19 mRNA vaccines
Article Snippet: .. In contrast, 38 in uncapped RNAs, translation may also proceed through internal ribosome entry site (IRES), 39 which recruits ribosomes independent of the 5′ cap.4,5 Such IRES-mediated initiation is 40 widely exploited by RNA viruses to ensure protein synthesis under conditions that suppress 41 host cap-dependent translation.4,5 42 Approved COVID-19 mRNA vaccines rely exclusively on cap-dependent translation and 43 employ optimized 5′UTRs to maximize cap-dependent translation and antigen yields.1,6 For 44 example, Moderna’s mRNA-1273 (Spikevax) uses a synthetic 57-nt 5′UTR, while the Pfizer–45 BioNTech BNT162b2 vaccine employs a sequence derived from the 5′UTR of human α-46 globin (HBA1) mRNA.6 In contrast, CureVac’s first-generation vaccine CVnCoV used a very 47 short artificial 5′UTR sequence.7 Its second-generation vaccine, CV2CoV, incorporated a 48 longer, optimized 5′UTR derived from human hydroxysteroid 17β-dehydrogenase 4 49 (HSD17B4), resulting in improved antigen expression and enhanced immunogenicity.7 These 50 Jo urn al Pr e-p roo f 3 examples highlight the 5′UTR as a key determinant of mRNA translational potency and 51 overall vaccine performance. ..

Expressing:

Article Title: A transferable SARS-CoV-2 IRES module enables dual translation initiation for enhanced antigen expression in COVID-19 mRNA vaccines
Article Snippet: .. In contrast, 38 in uncapped RNAs, translation may also proceed through internal ribosome entry site (IRES), 39 which recruits ribosomes independent of the 5′ cap.4,5 Such IRES-mediated initiation is 40 widely exploited by RNA viruses to ensure protein synthesis under conditions that suppress 41 host cap-dependent translation.4,5 42 Approved COVID-19 mRNA vaccines rely exclusively on cap-dependent translation and 43 employ optimized 5′UTRs to maximize cap-dependent translation and antigen yields.1,6 For 44 example, Moderna’s mRNA-1273 (Spikevax) uses a synthetic 57-nt 5′UTR, while the Pfizer–45 BioNTech BNT162b2 vaccine employs a sequence derived from the 5′UTR of human α-46 globin (HBA1) mRNA.6 In contrast, CureVac’s first-generation vaccine CVnCoV used a very 47 short artificial 5′UTR sequence.7 Its second-generation vaccine, CV2CoV, incorporated a 48 longer, optimized 5′UTR derived from human hydroxysteroid 17β-dehydrogenase 4 49 (HSD17B4), resulting in improved antigen expression and enhanced immunogenicity.7 These 50 Jo urn al Pr e-p roo f 3 examples highlight the 5′UTR as a key determinant of mRNA translational potency and 51 overall vaccine performance. ..

Immunopeptidomics:

Article Title: A transferable SARS-CoV-2 IRES module enables dual translation initiation for enhanced antigen expression in COVID-19 mRNA vaccines
Article Snippet: .. In contrast, 38 in uncapped RNAs, translation may also proceed through internal ribosome entry site (IRES), 39 which recruits ribosomes independent of the 5′ cap.4,5 Such IRES-mediated initiation is 40 widely exploited by RNA viruses to ensure protein synthesis under conditions that suppress 41 host cap-dependent translation.4,5 42 Approved COVID-19 mRNA vaccines rely exclusively on cap-dependent translation and 43 employ optimized 5′UTRs to maximize cap-dependent translation and antigen yields.1,6 For 44 example, Moderna’s mRNA-1273 (Spikevax) uses a synthetic 57-nt 5′UTR, while the Pfizer–45 BioNTech BNT162b2 vaccine employs a sequence derived from the 5′UTR of human α-46 globin (HBA1) mRNA.6 In contrast, CureVac’s first-generation vaccine CVnCoV used a very 47 short artificial 5′UTR sequence.7 Its second-generation vaccine, CV2CoV, incorporated a 48 longer, optimized 5′UTR derived from human hydroxysteroid 17β-dehydrogenase 4 49 (HSD17B4), resulting in improved antigen expression and enhanced immunogenicity.7 These 50 Jo urn al Pr e-p roo f 3 examples highlight the 5′UTR as a key determinant of mRNA translational potency and 51 overall vaccine performance. ..

Review